SPS (WITH SORBITOL) (sodium polystyrene sulfonate/sorbitol solution)
POTASSIUM-REMOVING RESINS · HYPERKALEMIA
CAROLINA MED.
Drug class
Potassium-Removing Resins
Potassium-removing resins are gastrointestinal cation-exchange polymers designed to lower elevated serum potassium levels. Read more about Potassium-Removing Resins
24 drugs in this class 18 manufacturers
Drugs in Potassium-Removing Resins
SPS (WITH SORBITOL) (sodium polystyrene sulfonate/sorbitol solution)
POTASSIUM-REMOVING RESINS · HYPERKALEMIA
CAROLINA MED.
SODIUM POLYSTYRENE SULFONATE
POTASSIUM-REMOVING RESINS · HYPERKALEMIA
SUNRISE PHARMAC
SODIUM POLYSTYRENE SULFONATE
POTASSIUM-REMOVING RESINS · HYPERKALEMIA
BLU PHARMACEUTI
SODIUM POLYSTYRENE SULFONATE
POTASSIUM-REMOVING RESINS · HYPERKALEMIA
ECI PHARMACEUTI
LOKELMA (sodium zirconium cyclosilicate)
POTASSIUM-REMOVING RESINS · HYPERKALEMIA
AstraZeneca Pharmaceuticals
SODIUM POLYSTYRENE SULFONATE
POTASSIUM-REMOVING RESINS · HYPERKALEMIA
BELCHER PHARMAC
SODIUM POLYSTYRENE SULFONATE
POTASSIUM-REMOVING RESINS · HYPERKALEMIA
ATLANTIC BIOLOG
SODIUM POLYSTYRENE SULFONATE
POTASSIUM-REMOVING RESINS · HYPERKALEMIA
ALEXSO INC
Filter & compare in the drug finder →
Opens the drug finder with Potassium-Removing Resins preselected. Add indication or manufacturer filters there.
Potassium-removing resins are gastrointestinal cation-exchange polymers designed to lower elevated serum potassium levels.
Administered orally or rectally, these non-absorbed agents pass through the digestive tract and bind potassium ions in exchange for cations such as sodium or calcium, facilitating potassium excretion in the stool.
Clinically, they are indicated for the management of hyperkalemia, particularly in patients with acute or chronic kidney disease, end-stage renal disease, or heart failure, frequently in individuals receiving renin-angiotensin-aldosterone system inhibitors.
-
nih.gov
Potassium-removing resins are gastrointestinal cation-exchange polymers designed to lower elevated serum potassium levels Clinically, they are indicated for the management of hyperkalemia, particularly in patients with acute or chronic kidney disease, end-stage renal disease, or heart failure, frequently in individuals receiving renin-angiotensin-aldosterone system inhibitors
-
drugoffice.gov.hk
Potassium-removing resins are gastrointestinal cation-exchange polymers designed to lower elevated serum potassium levels Administered orally or rectally, these non-absorbed agents pass through the digestive tract and bind potassium ions in exchange for cations such as sodium or calcium, facilitating potassium excretion in the stool
-
fda.gov
Potassium-removing resins are gastrointestinal cation-exchange polymers designed to lower elevated serum potassium levels Administered orally or rectally, these non-absorbed agents pass through the digestive tract and bind potassium ions in exchange for cations such as sodium or calcium, facilitating potassium excretion in the stool
-
fda.gov
Administered orally or rectally, these non-absorbed agents pass through the digestive tract and bind potassium ions in exchange for cations such as sodium or calcium, facilitating potassium excretion in the stool
-
fda.gov
Administered orally or rectally, these non-absorbed agents pass through the digestive tract and bind potassium ions in exchange for cations such as sodium or calcium, facilitating potassium excretion in the stool
-
frontierspartnerships.org
Clinically, they are indicated for the management of hyperkalemia, particularly in patients with acute or chronic kidney disease, end-stage renal disease, or heart failure, frequently in individuals receiving renin-angiotensin-aldosterone system inhibitors
-
globalrx.com
Clinically, they are indicated for the management of hyperkalemia, particularly in patients with acute or chronic kidney disease, end-stage renal disease, or heart failure, frequently in individuals receiving renin-angiotensin-aldosterone system inhibitors
-
drugdiscoverytrends.com
Clinically, they are indicated for the management of hyperkalemia, particularly in patients with acute or chronic kidney disease, end-stage renal disease, or heart failure, frequently in individuals receiving renin-angiotensin-aldosterone system inhibitors
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.